![UPDATE 2-Celgene's drug for anemia in beta thalassemia priced at $3,441/ 25 mg vial]( "UPDATE 2-Celgene's drug for anemia in beta thalassemia priced at $3,441/ 25 mg vial")
Celgene Corp’s treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc said. The drug was jointly developed by Acceleron and Celgene, which is being bought by Bristol-Myers Squibb Co. A 75 mg vial of Reblozyl will be available at a wholesale acquisition cost of $10,323.53 per vial, Acceleron said.
